{"name":"LTZ Therapeutics, Inc.","slug":"ltz-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"LTZ Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address significant unmet medical needs. The company's lead candidate, LTZ-301, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQX09kVTZUVEJjTlpMdmR1djV4VnIyVDVKRlllbTE4XzNkSnVsSkd1Q0dWTExaVUd1cU5lUlozMDByUTN2MW1ZbWFkc1IwT0xvYlZ1bE9JdFFqZVh2Nm1aV2RBanVOdzByZTRfRXdhV2U5aWp5ZE9xSjlWLXk4b2p0TGV5cl8zOXp6VkRWaXpZVE41czdmTWhmeXlZakI0SHZHRjlSaFVQcEhVOEFQT29OZkFySktsbU9VMVdkX2NDWjhXTkRtQUZxdlpLWUxoR01UUDlHQnVJZ1puSFk?oc=5","date":"2025-11-19","type":"deal","source":"GSK","summary":"GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology - GSK","headline":"GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOMUl2dXR0djExbDlwd0ZBRE9wOXhpbVVqVzNQTkEwS3g3ZThQaVRIN1lJUkUzYVVNRnlIRnZDWl93MzZySHlMQVJLano0eFJxQ2J5NExxYllFd3NSallDSnU5bVJtcHdEUXlLU2FXWnhDaW5SZWVMMGlZdF9FZ2JYX09lamw1MVlhN1RmWnBPeTlqd2s?oc=5","date":"2025-11-19","type":"deal","source":"BioWorld News","summary":"GSK, LTZ partner to develop myeloid cell engagers - BioWorld News","headline":"GSK, LTZ partner to develop myeloid cell engagers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPREtRNFFSN0xPSjFDTnhQYmk0dU9jcDdlU200QzUtbTNUbTIyenMwSGdfQ3JVSnRuZG41UkNXTW01LUpFY3JadFh3SVN5ZnB5c0daTi1ucERiblR3N2U0Z3FCd1NlOEZoYU40OFo3cnROeHphZUVNbjFFY19YR2lyeENGemU?oc=5","date":"2025-07-30","type":"trial","source":"Yahoo Finance","summary":"Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration - Yahoo Finance","headline":"Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPb3A2NTZHX1NEeXlIUUt6TURPcDBDY0paX1B3SWl2djFxVHJfMjEtRlZ2dTRDRHR0Rnc1NXl4Z0VQdzlFdUo1VE1uVUlORUVRdGJDMTJSRzZiMzZpR09QMGFhcEN2SkkwS09NemcyQ0R3QVVOcnBTQWdaenl4WFR0ZzdIMzNEclpJakJUOEVWRFpMbGRNYlViN2k4WGhVM2cyUGFnRmJIeE9tOU1PeXBablhVZFZfVTBqSHpzaHZjMXlteWZqeklKTTZGeWZ0VmRxZ255UVlkYzNqdDBrWnAwQTNqUERNV3JOY1prQXJpODFrb0Z6aWxqYVFGZnhSWG1Pdlc1aHA5OVpLV2ZtMU5zU0ZDT1ZpdG9hcGhyN2stYWE4UkF2X3hXUQ?oc=5","date":"2025-07-29","type":"deal","source":"Business Wire","summary":"LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases - Business Wire","headline":"LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNUDRSQTE5WC10a3dtU2dTak1LcnZReGVVNnF2M0stc0IwTUVlZ0tQcVlTcmY3VHJHODNqT056VmJQTUJtMVM3bTJrZXVtOE50dkk1MG0zellKYktRZUg3WTNmVUpyazNtam1SNWwwWHctbW1oVFdWaTRJVFJ4QUpOazQwOGNUQ0h2aUxTQlFadGJVSmhQZnd0M1VEdVpESFZ1QTZuNmFDN0RyUmhaZzdn?oc=5","date":"2025-04-25","type":"pipeline","source":"The Pharma Letter","summary":"LTZ bags $40 million as it sends first myeloid engager into clinic - The Pharma Letter","headline":"LTZ bags $40 million as it sends first myeloid engager into clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBBWU81NENQTWtIcVJNV1VIZUlBdGZxNG5faVNFaHhIS1BNRm92S0JYYlZYUEFwMERzU2lIbWFXR3dPU1dvMlBJQlpBNXdCM1UxSGoxM2J3TjlpRlZQTzYzTmRDNTJJbFRSTHFGdUoyR3ZfbmlfelJOcUln?oc=5","date":"2025-03-05","type":"trial","source":"Oncology Pipeline","summary":"T-cell engagement with a difference | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"T-cell engagement with a difference | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNanFpQ0QwSERwYlhSMVZ3VTNvMHFzM2VldHptLUF3LV9xeWdWVmVrYzROMGFEUkVWbGtETkRhMDhRRGs4UVFFRUdidm9pX2tYZ0xCLUVNS0pZWWFKZXFpdUd1VUtmak1mODBQa0paVnRhVm5GWTk0VExzUnE0ankwbzZMOXRBZloyNnh2Vk9LdDBVdkdnU2R5eTlwZ3FiZFRIdTZSQURHUHRKQWZEclRXR04zM2ZDT0ZSZGJQaUJFS2lTVm1CZUFHSXRBREpZbXI0UjJySzZBMEl4T25DWXMtcVNBQ1N1LUNCUlB2aEZxaHdCNFp6N0s5Y2NudzZpTHhrNDV6QkdkY3owN2I5OVZHb21kd1pObTI4Unc?oc=5","date":"2025-02-24","type":"regulatory","source":"Business Wire","summary":"LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 - Business Wire","headline":"LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunoth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQakxCRThWU3NqOWlDak9aeFNTUkdoQzRPdldpZGlUcTd0YVpqT3pLNXF1dE9rZE5jUzFOcWJlczAwUGZSanI2cDEtMmQ1c3V0MlFweVZxdmhfVmNVMUVDT1N2Y0lyUGU4YXpfOW1PeG8wcllKcTg2QmRwczFMOWZaQjBTdHROMlRlbEVxdDhseW13Rm9rUFNiYWtFMzU3Z0wtckVj?oc=5","date":"2023-05-31","type":"pipeline","source":"BioWorld News","summary":"LTZ raises $10M in pre-series A+ to advance lead immunotherapy - BioWorld News","headline":"LTZ raises $10M in pre-series A+ to advance lead immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxNUlJOTHZTS1cxSkhhUjJSeHNmUHFEdUNpSEFHb1BVVnZnOVJYX250REpJMXI3UkNuLXBTem5QQ2NINjdBdm9SSUl1cnFhMng2R0gzN0FxQ2lzVHBoTEp0eUs1dWs0bGJzeUl0c0F0LVJEZG5NN3hmbEp5MWNicmJTM2ZuZVZqSkFDMkJvaU9mMU90c1hCX25uQ01MalRxOFlYakhLdDZIa0VzZ1dEcW90eFNHeGhFeFBuRF9oM2hPRTZON2l3ZXUtWDRTb1p4NGJhUERrUmQ0MDVXZC05dklTcXFVcEdSTW1ST2dEM3RiNUhwTHdJbzV0cndzWU1VU3FVdFJmZ0FQVk1rVGFzdGM1THlld1BBTXdFdUctQjA0TEtGYk1r?oc=5","date":"2023-05-31","type":"pipeline","source":"Business Wire","summary":"LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases - Business Wire","headline":"LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}